Your decision: expected, verify, or refer

Three follow-up lipid results come across the bench in the same shift, each on a patient with a documented lipid-lowering therapy change. Sort each into one of three buckets: an expected pattern for the drug class and timing, a result that needs specimen or method verification before it is trusted, or a pattern that is internally consistent and analytically sound but needs clinical correlation because the laboratory cannot resolve it from the data alone.

Patient one is on fenofibrate for severe hypertriglyceridemia. Baseline triglycerides were 620 mg/dL, so Friedewald LDL-C was not valid at baseline. Follow-up triglycerides are 240 mg/dL and LDL-C is now calculable and higher in absolute terms than expected from the triglyceride drop alone. This labeled paradoxical LDL-C rise can reflect VLDL/remnant-to-LDL remodeling as triglycerides fall; without a valid baseline Friedewald LDL-C, the two calculated LDL-C values are not a comparable pair.

Patient two started a statin four months ago. Lp(a), drawn once as part of baseline cardiovascular risk assessment, comes back at a level higher than a value drawn two years earlier by a different laboratory. The current LDL-C result is available for the ordering clinician to interpret in the applicable risk context. Statins do not lower Lp(a) and may cause a small average increase; Lp(a) is also largely genetically determined and stable, and a shift here is more likely explained by different assay methods (mass-based versus particle-based) between the two draws than by a true biological change, and neither explanation is a reason to flag nonadherence.

Patient three has been on unchanged high-intensity statin therapy for a year with prior LDL-C consistently near 60 mg/dL. The current result is 210 mg/dL, with non-HDL-C not falling in proportion, and the ordering system shows the analyzer's LDL-C calculation method was switched to a different equation two weeks earlier. This is the internally inconsistent case: a sharp, unexplained rise on unchanged therapy, together with a documented method change and a mismatch between LDL-C and non-HDL-C, is a signal to verify calculation inputs and method continuity before the result is released as a treatment-related finding.

Sorting a lipid trend into expected, needs-verification, or needs-clinical-correlation before release is the laboratory's contribution under a documented result-consistency review procedure; the laboratory does not decide whether the drug is working or failing.